Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.

@article{Ngrier2018PostauthorizationSS,
  title={Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.},
  author={Claude N{\'e}grier and Anne-Sophie Ducloy-Bouthors and Vincent Piriou and Emmanuel de Maistre and Natalie Stieltjes and Annie Borel-Derlon and P H Colson and Julien Picard and Thomas Lambert and S{\'e}gol{\`e}ne Claeyssens and Sylvie Boileau and Anne Bertrand and M-H Andr{\'e} and François Fourrier and Yves M Ozier and Pi{\`e}rre Si{\'e} and Yves Gruel and Z Tellier},
  journal={Vox sanguinis},
  year={2018},
  volume={113 2},
  pages={
          120-127
        }
}
BACKGROUND AND OBJECTIVES A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact® in acquired fibrinogen deficiency in real-life medical practice in France. MATERIALS AND METHODS One hundred and fifty patients were planned for 28 days of prospective follow-up after infusion. The analysis of this… CONTINUE READING